TY  - JOUR
TI  - Urticarial Vasculitis After First Denosumab Injection  in an Osteoporotic Woman Diagnosed with  Cushing’s Syndrome
AB  - Denosumab is a human-derived monoclonal immunoglobulin G2 antibody against the receptor  activator of nuclear factor kappa B ligand, inhibiting the differentiation and function of osteoclast  precursor cells by its antiosteoclastic action. Denosumab is approved for postmenopausal, glucocorti coid-induced, and male osteoporozis with high risk of fracture. The use of denosumab has increased  in recent years. While new medications continue to be developed, the number of agents causing  drug-induced vasculitis is expected to increase. It may be a good strategy to identify risk factors for  vasculitis development and look for these factors before drug administration. Here, we present a rare  complication of denosumab, urticarial vasculitis, after the first denosumab injection in an osteopo rotic woman diagnosed with Cushing’s syndrome.
AU  - imre, eren
AU  - Gogas Yavuz, Dilek
AU  - Şeker, Aysun
DO  - 10.5152/tjem.2022.22012
PY  - 2022
JO  - Turkish Journal of Endocrinology and Metabolism
VL  - 26
IS  - 3
SN  - 1301-2193
SP  - 181
EP  - 183
DB  - TRDizin
UR  - http://search/yayin/detay/1124146
ER  -